Manvel, TX, United States of America

Jacqulyne Robichaux

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Location History:

  • Manvel, TX (US) (2022)
  • Houston, TX (US) (2022)

Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Jacqulyne Robichaux

Introduction

Jacqulyne Robichaux is an accomplished inventor based in Manvel, Texas. She has made significant contributions to the field of cancer treatment through her innovative research and patented inventions. With a total of two patents, her work focuses on developing compounds that target specific mutations in cancer cells.

Latest Patents

Robichaux's latest patents include "Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations." This patent provides methods for treating cancer in patients with these specific mutations by administering third-generation tyrosine kinase inhibitors, such as poziotinib or afatinib. Another notable patent is "Heterocyclic inhibitors of tyrosine kinase," which relates to heterocyclic compounds and methods that may serve as inhibitors of HER2 or EGFR for the treatment or prevention of diseases, including cancer.

Career Highlights

Jacqulyne Robichaux is affiliated with the University of Texas System, where she conducts her research and develops her innovative solutions. Her work has garnered attention in the scientific community for its potential impact on cancer therapies.

Collaborations

Some of her notable coworkers include John V Heymach and Monique Nilsson, who contribute to her research efforts and advancements in the field.

Conclusion

Jacqulyne Robichaux's contributions to cancer treatment through her patented inventions highlight her role as a leading innovator in the medical field. Her work continues to pave the way for new therapeutic options for patients with specific cancer mutations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…